Clinical Trials Browser

Phase 1/2 × Prostatic Neoplasms × Imatinib Mesylate × Clear all

NCT00861471 2016-06-30

Docetaxel (Taxotere) and Imatinib Mesylate (Gleevec) in Hormone Refractory Prostate Cancer

Phase 1/2 Terminated

24 enrolled 11 charts

Prostatic Neoplasms